A Low-Cost Handheld Device for Monitoring Cutaneous Photosensitivity
- 1Department of Physics, University of Massachusetts Boston, Boston, MA, USA
- 2Massachusetts General Hospital, Harvard Medical School, Wellman Center for Photomedicine, Boston, Massachusetts, USA
- 3Harvard University and Massachusetts Institute of Technology, Division of Health Sciences and Technology, Cambridge, Massachusetts, USA
Abstract
Photodynamic therapy (PDT) has been shown to be clinically effective for multiple cancers with low side effects and minimal off‐target toxicity in comparison to traditional anticancer drugs. One of the only widely noted safety considerations for PDT is the potential for residual cutaneous photosensitivity after treatment, especially for protocols where the photosensitizer is administered systemically. The need to monitor cutaneous photosensitivity is particularly important for the implementation of PDT in resource‐limited settings where overnight hospitalization is not available. Here, we report a compact, low‐cost, cutaneous photosensitivity detection (CPD) device enabling real‐time, contact‐based fluorescence quantification that can be used as a home health solution for assessing cutaneous phototoxicity risk. The prototype device uses a 405 nm excitation LED, a long‐pass emission filter (> 600 nm), and a photodiode to measure protoporphyrin IX (PpIX) fluorescence. Validation in tissue‐mimicking phantoms, TR146 oral squamous carcinoma cell models, and murine in vivo studies demonstrates sensitivity within the clinically relevant submicromolar regime ( R 2 > 0.9), accurate capture of aminolaevulinic acid‐induced PpIX kinetics, and strong concordance with fluorescence spectroscopy measurements and imaging using a commercial in vivo imaging system. To model the effect of epidermal melanin, we also measure the fluorescence signal as a function of phantom pigmentation using coffee. To further investigate the role of epidermal melanin in attenuating blue excitation light used by this hardware, we ran a series of Monte Carlo simulations modeling light propagation in skin with varying percent melanin corresponding to a range of Fitzpatrick skin types. This study sets the stage for clinical validation of the CPD device as a tool for personalized photoprotection and data‐driven discharge decisions following PDT, with relevance for point‐of‐care and resource‐limited settings.
Related
- The Need for Device-Specific Training Before Handheld Ultrasound Use: Agreement and Repeatability of Simulated Aortic Aneurysm Diameter Measurements by Senior Sonography Students on a Familiar Conventional and an Unfamiliar Handheld System
- Cutaneous warning signs of cardiac implantable electronic device infection: a pictorial guide for clinicians
- A simple and minimally invasive device for skin sampling and molecular detection in cutaneous fungal infections
- A Low-Cost Device for Teaching Surgical Techniques and Evaluating Technology in Minimally Invasive Surgery
- Real-World Direct Medical Costs and Clinical Outcomes of Immunotherapy and Targeted Therapy for Cutaneous Melanoma: A Bottom-Up Cost-of-Illness Study in a Public Healthcare System
BibTeX
@article{rasel2026lowcost,
title = {{A Low-Cost Handheld Device for Monitoring Cutaneous Photosensitivity}},
author = {Md Asaduzzaman Rasel and Ryan Beland and Shakir Khan and Tayyaba Hasan and Jonathan P. Celli},
journal = {Photochemistry and photobiology},
year = {2026},
month = jul,
doi = {10.1111/php.70140},
url = {https://doi.org/10.1111/php.70140},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - A Low-Cost Handheld Device for Monitoring Cutaneous Photosensitivity
AU - Md Asaduzzaman Rasel
AU - Ryan Beland
AU - Shakir Khan
AU - Tayyaba Hasan
AU - Jonathan P. Celli
PY - 2026
DA - 2026/07/31
JO - Photochemistry and photobiology
DO - 10.1111/php.70140
UR - https://doi.org/10.1111/php.70140
AB - Photodynamic therapy (PDT) has been shown to be clinically effective for multiple cancers with low side effects and minimal off‐target toxicity in comparison to traditional anticancer drugs. One of the only widely noted safety considerations for PDT is the potential for residual cutaneous photosensitivity after treatment, especially for protocols where the photosensitizer is administered systemically. The need to monitor cutaneous photosensitivity is particularly important for the implementation of PDT in resource‐limited settings where overnight hospitalization is not available. Here, we report a compact, low‐cost, cutaneous photosensitivity detection (CPD) device enabling real‐time, contact‐based fluorescence quantification that can be used as a home health solution for assessing cutaneous phototoxicity risk. The prototype device uses a 405 nm excitation LED, a long‐pass emission filter (> 600 nm), and a photodiode to measure protoporphyrin IX (PpIX) fluorescence. Validation in tissue‐mimicking phantoms, TR146 oral squamous carcinoma cell models, and murine in vivo studies demonstrates sensitivity within the clinically relevant submicromolar regime ( R 2 > 0.9), accurate capture of aminolaevulinic acid‐induced PpIX kinetics, and strong concordance with fluorescence spectroscopy measurements and imaging using a commercial in vivo imaging system. To model the effect of epidermal melanin, we also measure the fluorescence signal as a function of phantom pigmentation using coffee. To further investigate the role of epidermal melanin in attenuating blue excitation light used by this hardware, we ran a series of Monte Carlo simulations modeling light propagation in skin with varying percent melanin corresponding to a range of Fitzpatrick skin types. This study sets the stage for clinical validation of the CPD device as a tool for personalized photoprotection and data‐driven discharge decisions following PDT, with relevance for point‐of‐care and resource‐limited settings.
SN - 0031-8655
SN - 1751-1097
ER -